Share

GICC 2016 will highlight primary therapy of early GI cancer with a focus on pancreatic and biliary cancer

The 3rd St. Gallen International Gastrointestinal Cancer Conference, #GICC2016, will address primary therapy of early GI cancer with a strong focus on pancreatic and biliary cancer. This conference will be held in St. Gallen, Switzerland from 10-12 March 2016.

The interactive program offers sessions on cystic neoplasms of the pancreas, extrahepatic cholangiocarcinoma, cancer of the ampulla of vater, understanding pancreatic cancer, resectable pancreatic cancer, borderline resectable pancreatic cancer, and improving outcome in pancreatic cancer.

Keynote lectures will be given by Dr Manuel Hidalgo of the Spanish National Cancer Research Centre on Molecular biology of pancreatic cancer and by Dr Andrew Rhim of the University of Michigan Medical School on Complex roles of the stroma in pancreatic cancer.

A special session concerning optimal primary therapy of pancreatic cancer will seek consensus on evidence and opinions about the optimal treatment of pancreatic cancer. This session will allow conference participants to share their thoughts on this area of GI cancer as well as benefit from the views and opinions of experts in the field.

There will also be poster exhibitions, an exhibition hall, and industry sponsored satellite symposiums.

Abstract submission is open until 15 December 2015.

Back to news list

Related News

  • Professor Benjamin Besse becomes President of EORTC

  • CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

  • EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials

  • New study confirms a key quality of life tool can be used with adolescents with cancer

  • “Changing practice, improving lives”: EORTC publishes its Annual Report 2025

  • This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research

  • Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer

  • Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma

  • EORTC’s presence at ESTRO 2026

  • Independent, academic cancer trials are vital to improve patient outcomes worldwide